Precision oncology’s translation gap—Can molecular tumor boards bridge it?

Margaret M Byrne and Jill M Kolesar

PLOS Medicine, 2026, vol. 23, issue 6, 1-4

Abstract: Precision oncology is revolutionizing cancer care, but isn’t reaching enough patients. Molecular tumor boards (MTBs) translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. But how can we feasibly and equitably expand the use of MTBs?Molecular tumor boards translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. In this Perspective, Margaret Byrne and Jill Kolesar discuss how we may feasibly and equitably expand the use of MTBs.

Date: 2026
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005165 (text/html)
https://journals.plos.org/plosmedicine/article/fil ... 05165&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pmed00:1005165

DOI: 10.1371/journal.pmed.1005165

Access Statistics for this article

More articles in PLOS Medicine from Public Library of Science
Bibliographic data for series maintained by plosmedicine ().